Stock listing

NASDAQ:INBX Inhibrx Biosciences, Inc. Stock

Home listing (NASDAQ) of Inhibrx Biosciences, Inc.

Follow Inhibrx Biosciences, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:INBX

$68.97 USD -0.09 (-0.1%)

Close on Nov 20, 2026

Past year -13.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$68.78 – $74.45 USDNov 20, 2026
Volume
252,126 sharesNov 20, 2026
Market cap
$1.02B USDAt the close on Nov 20, 2026 · price × 14.72M shares outstanding
52-week range
$57.30 – $155.29 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$29.86M USDMedian day 242,218 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Inhibrx Biosciences, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:INBX · Home$68.97 USD-0.09 (-0.1%)252,126$72.72$74.45$68.78$69.06Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:INBX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$68.97-0.09-0.1%$72.72$74.45$68.78252,126
$69.06-5.12-6.9%$74.21$75.42$68.27288,906
$74.18-3.48-4.5%$78.21$78.21$72.95300,129
$77.66-5.64-6.8%$80.28$84.71$76.50286,042
$83.30-4.445-5.1%$87.91$87.91$80.95245,896
$87.75-2.845-3.1%$88.56$91.13$86.00226,482
$90.59-0.020.0%$92.38$93.48$89.39165,638
$90.61-1.13-1.2%$90.31$92.90$90.01100,296
$91.74+7.22+8.5%$86.40$93.45$84.83185,736
$84.52+4.24+5.3%$80.68$85.57$79.47220,135
$80.28-6.48-7.5%$86.00$86.75$79.35242,218
$86.76+5.68+7.0%$83.95$87.13$82.13190,181
$81.08+8.92+12.4%$71.16$83.00$71.16600,229
$72.16+0.38+0.5%$72.45$73.49$70.87234,349
$71.78-1.87-2.5%$72.04$73.03$66.80438,800
$73.65+0.36+0.5%$73.75$75.72$71.75358,700
$73.29-22.37-23.4%$94.55$96.79$69.271,188,600
$95.66+7.05+8.0%$88.52$99.88$88.52373,900
$88.61-4.77-5.1%$93.80$94.46$86.92251,200
$93.38-3.72-3.8%$96.96$96.99$92.50176,200
$97.10-1.09-1.1%$96.94$100.20$94.04249,500
$98.19+2.89+3.0%$98.10$99.82$93.00239,300
$95.30+5.51+6.1%$89.07$96.50$88.99221,400
$89.79-0.040.0%$90.43$92.98$88.21156,100
$89.83-0.67-0.7%$89.83$90.72$87.73146,400
$90.50+5.24+6.1%$87.60$91.68$87.20226,400
$85.26-1.82-2.1%$86.23$87.36$83.61246,100
$87.08-3.45-3.8%$90.11$92.46$85.80271,300
$90.53-4.48-4.7%$94.03$96.10$90.00216,100
$95.01+2.25+2.4%$92.70$95.81$92.7086,800
$92.76-0.60-0.6%$93.14$93.28$90.15208,000
$93.36-0.05-0.1%$92.02$96.71$90.66223,800
$93.41-1.15-1.2%$95.52$96.96$92.60169,400
$94.56-2.43-2.5%$97.56$98.51$94.18206,900
$96.99-0.94-1.0%$99.30$100.13$96.07201,400
$97.93-2.15-2.1%$100.71$102.16$97.58216,600
$100.08-4.75-4.5%$105.67$106.94$100.08389,500
$104.83+3.12+3.1%$105.31$107.90$102.51240,900
$101.71+2.10+2.1%$98.69$104.55$98.51188,100
$99.61-0.79-0.8%$101.29$101.29$98.09158,700
$100.40+0.07+0.1%$102.38$104.49$99.53285,700
$100.33-10.34-9.3%$110.12$110.88$98.56375,300
$110.67-1.37-1.2%$112.45$117.14$109.05292,100
$112.04+2.69+2.5%$112.69$113.19$108.95249,100
$109.35+4.62+4.4%$106.45$110.41$105.04483,400
$104.73+2.96+2.9%$103.73$108.00$103.73216,600
$101.77-3.84-3.6%$105.61$106.44$99.06363,500
$105.61-4.86-4.4%$109.44$109.44$104.85251,600
$110.47+1.20+1.1%$109.10$111.44$104.90240,000
$109.27-2.15-1.9%$113.00$115.11$108.93211,000
$111.42-1.44-1.3%$109.23$113.95$107.22313,900
$112.86-1.48-1.3%$117.38$128.54$112.03677,800
$114.34-6.83-5.6%$117.22$120.18$94.001,672,200
$121.17-1.09-0.9%$121.04$124.19$120.48194,600
$122.26-2.71-2.2%$125.20$126.00$120.17151,700
$124.97+0.31+0.2%$125.61$127.75$121.25189,900
$124.66-2.04-1.6%$124.98$129.88$120.62275,600
$126.70+3.29+2.7%$123.39$128.87$121.59389,000
$123.41-0.52-0.4%$123.80$126.04$119.38241,500
$123.93-1.41-1.1%$124.27$127.34$122.36310,900
$125.34+2.62+2.1%$123.00$131.01$119.44302,900
$122.72+17.78+16.9%$105.50$126.50$104.71510,600
$104.94+1.31+1.3%$105.00$105.14$94.20373,500
$103.63+4.48+4.5%$100.76$105.65$99.05220,700
$99.15-2.33-2.3%$98.65$102.50$96.57351,500
Ticker
NASDAQ:INBX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Inhibrx Biosciences, Inc. news

Inhibrx Biosciences, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 26 in all · newest Nov 17, 2026 · oldest 2024
Decks
36 decks · latest Nov 13, 2026

Where Inhibrx Biosciences, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:INBX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:INBXBOATSUnited StatesUSD

Valuation

EV/sales 546× against a median of 9.3×: the highest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.09B USD
P/E
Loss
EV/sales
546×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
Negative equity
Beta vs S&P 500
1.89

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Inhibrx Biosciences, Inc. · NASDAQ:INBXUS$1.02BUS$1.09Bn/a546×n/an/an/an/a1.89
MedinCell SA · EURONEXT:MEDCLUS$1.05BUS$1.02Bn/a38.4×n/a313×−128.9%18.7×n/a
Nektar Therapeutics · NASDAQ:NKTRUS$1.03BUS$492.8Mn/a9.4×n/a1.2×−339.7%0.1×1.28
Mabwell (Shanghai) Bioscience Co., Ltd. Class A · SSE:688062US$1.02BUS$984.8Mn/a9.2×n/a9.5×−146.4%2.9×n/a
SpyGlass Pharma, Inc. · NASDAQ:SGPUS$1.02BUS$809.5Mn/an/an/a4.8×n/a0.0×1.01
Alto Neuroscience, Inc. · NYSE:ANROUS$1.02BUS$711.7Mn/an/an/a3.4×n/a0.1×1.65
Duality Biotherapeutics, Inc. · HKEX:9606US$992.3MUS$609.0Mn/a4.8×n/a4.6×−170.8%0.3×n/a
Peptron, Inc. · KRX:087010US$985.3MUS$948.0Mn/a211×n/a10.2×−342.2%0.2×n/a
Omeros Corporation · NASDAQ:OMERUS$983.7MUS$920.3M10.0×12.4×n/an/a132.3%n/a1.64
Everest Medicines Ltd. · HKEX:1952US$981.5MUS$1.00Bn/a2.8×183×1.3×−2.2%0.4×n/a
HBM Holdings Ltd. · HKEX:2142US$981.4MUS$711.5M10.7×4.5×8.6×2.4×57.8%0.2×n/a
Median of the othersUS$1.00BUS$864.9M10.4×9.3×95.9×4.6×−137.6%0.2×1.46

Forecasts

3 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.

Price target
266.67 USD · Analysts' mean
EPS, year to Dec 2026
-9.26 · 2 analysts

Team and board

Officers

OfficerRole
Mark P. LappeFounder, Chief Executive Officer
Kelly DeckEVP, Chief Financial Officer
David MatlyPresident
Leah PollemaVP, General Counsel
Ashraf AmanullahEVP, Chief Technical Operations Officer
Bonne AdamsVP, Operations
Brian LoboVP, Formulation Development and Drug Product Manufacturing
Carlos BaisEVP, Chief Scientific Officer
Dana Ebbets-ReedVP, Quality Assurance
Darren BrownVP, Analytical Development and Quality Control
David KaoVP, Regulatory Affairs
Josep GarciaEVP, Chief Clinical Development Officer
Kate Burke C.P.A.VP, Accounting
Melissa MastersonVP, Access and Commercialization
Robert BoothroydVP, Medical Affairs and Business Development
Sean FlanaganVP, Sales

Board

DirectorRole
Mark P. LappeFounder, Chief Executive Officer
Douglas G. ForsythDirector
Jon Faiz KayyemDirector
Kimberly ManhardDirector
Kristiina VuoriDirector

Events

QuarterResultsShare move
Q3 2026Nov 13, 2026 · After close−6.8%
Q2 2026Aug 13, 2026 · After close−8.9%
Q1 2026May 14, 2026 · After close−6.5%
Q4 2025Mar 23, 2026+3.6%
Q3 2025Nov 14, 2025 · Before open+6.0%
Q2 2025Aug 13, 2025 · After close+1.6%
Q1 2025May 14, 2025 · After close+10.9%
Q4 2024Mar 17, 2025−0.7%
Q3 2024Nov 14, 2024 · After close−3.5%
Q2 2024Aug 13, 2024+0.4%
All 11 quarters
QuarterResultsShare move
Q1 2024May 29, 2024

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck44 slidesNov 13, 2026
Technical Presentation (October 2026)Technical16 slidesOct 25, 2026
Investor Presentation (September 2026)Investor deck44 slidesSep 28, 2026
Investor Presentation (September 2026)Investor deck40 slidesSeptember 2026
Investor Presentation (September 2026)Investor deck26 slidesSeptember 2026
Investor Presentation (September 2026)Investor deck24 slidesSeptember 2026
Investor Presentation (August 2026)Investor deck28 slidesAugust 2026
Investor Presentation (June 2026)Investor deck27 slidesJune 2026
Investor Presentation (April 2026)Investor deck27 slidesApr 21, 2026
Investor Presentation (March 2026)Investor deck26 slidesMarch 2026
All 36 decks
DeckKindSlidesDate
BSG Annual Meeting 2026Conference17 slidesFebruary 2026
Investor Presentation (November 2025)Investor deck38 slidesNovember 2025
Investor Presentation (October 2025)Investor deck35 slidesOctober 2025
Investor Presentation (August 2025)Investor deck33 slidesAugust 2025
Investor Presentation (May 2025)Investor deck33 slidesMay 2025
Investor Presentation (March 2025)Investor deck33 slidesMarch 2025
Investor Presentation (January 2025)Investor deck33 slidesJanuary 2025
Investor Presentation (January 2025)Investor deck34 slidesJanuary 2025
Investor Presentation (August 2024)Investor deck25 slidesAug 13, 2024
Investor Presentation (June 2024)Investor deck23 slidesJune 2024
Investor Presentation (September 2023)Investor deck36 slidesSeptember 2023
Investor Presentation (August 2023)Investor deck36 slidesAugust 2023
Investor Presentation (April 2023)Investor deck48 slidesApril 2023
Investor Presentation (March 2023)Investor deck47 slidesMarch 2023
ASCPT 2023Conference10 slidesMarch 2023
Investor Presentation (November 2022)Investor deck46 slidesNovember 2022
Investor Presentation (August 2022)Investor deck49 slidesAugust 2022
Investor Presentation (July 2022)Investor deck44 slidesJuly 2022
Investor Presentation (May 2022)Investor deck44 slidesMay 2022
Investor Presentation (February 2022)Investor deck41 slidesFebruary 2022
Investor Presentation (January 2022)Investor deck41 slidesJanuary 2022
Investor Presentation (November 2021)Investor deck39 slidesNovember 2021
Investor Presentation (June 2021)Investor deck29 slidesJune 2021
Investor Presentation (January 2021)Investor deck31 slidesJanuary 2021
Investor Presentation (November 2020)Investor deck31 slidesNovember 2020
Investor Presentation (September 2020)Investor deck31 slidesSeptember 2020

Open Decks

Financings

RaiseDate
Term C Loan with warrants
Closed: US$100M raised · Warrants at US$93.21 for 120 months
Buyers: Oxford Finance LLC (funded the $100.0 million Term C Loan and received warrants to purchase 21,457 shares)
Use of proceeds: Advancing the ozekibart (INBRX-109) and INBRX-106 programs
Jul 16, 2026

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue1.30M200.0K1.80M2.19M7.13M12.8M9.09M8.60M8.39M6.67M
Cost of revenue2.48M2.29M1.19M110.2M2.69M73.5M47.9M33.5M25.5M17.0M
Gross profit-1.18M-2.08M609.0K-108.0M4.44M-60.7M-38.8M-24.9M-17.1M-10.3M
Research and development113.0M203.7M191.6M110.2M71.4M73.5M47.9M33.5M25.5M17.0M
Selling, general and administrative23.3M127.9M29.4M21.1M12.4M6.84M9.02M4.65M2.61M1.82M
Operating income-135.0M-331.4M-219.2M-129.1M-76.7M-67.4M-41.0M-29.5M-19.7M-12.1M
Depreciation and amortization2.48M2.29M1.19M1.23M1.20M1.02M1.16M676.0K399.0K253.0K
EBITDA-132.5M-329.2M-218.0M-127.9M-75.5M-66.4M-39.8M-28.8M-19.3M-11.9M
Interest expense12.2M13.5M31.8M16.1M5.22M10.8M5.72M1.48M2.13M
Income before tax-140.1M1.69B-239.7M-145.2M-81.8M-75.6M-50.5M-30.9M-21.8M-12.9M
Income tax2.00K2.00K3.00K3.00K2.00K3.00K898.0K96.0K250.0K-4.62M
Net income-140.1M1.69B-241.4M-145.2M-81.8M-76.1M-51.4M-31.2M-19.4M-8.27M
Earnings per share, basic-9.04114.01-20.48-3.62-2.15-3.01-1.41-1.15-0.68-0.23
Earnings per share, diluted-9.04112.62-20.48

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents124.2M152.6M277.9M273.9M131.3M128.7M11.5M2.10M13.5M20.0M
Receivables177.0K420.0K778.0K257.0K878.0K615.0K438.0K690.0K696.0K
Inventory-257.0K-878.0K-129.3M3.21M2.31M999.0K
Current assets132.8M160.4M295.4M280.5M139.1M132.2M15.6M5.66M15.4M20.4M
Property, plant and equipment3.73M6.20M6.42M
Total assets146.5M180.8M307.9M290.9M150.4M143.7M26.5M9.98M17.2M21.3M
Accounts payable5.94M9.24M11.0M8.33M9.13M13.5M3.12M6.53M775.0K167.0K
Current liabilities33.8M40.7M56.3M27.6M22.5M31.4M20.6M16.2M8.92M5.28M
Long-term debt100.6M0207.0M
Total debt100.6M0207.0M207.1M72.1M37.5M41.7M9.49M14.7M18.9M
Total liabilities138.5M47.2M264.4M232.8M98.1M68.3M120.1M67.6M39.7M20.0M
Shareholders' equity7.99M133.6M43.5M58.1M52.4M75.5M-93.6M-57.6M-28.8M-9.25M
Shares outstanding14.6M14.5M47.4M40.1M38.0M25.3M36.6M27.1M28.8M36.6M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-129.8M-194.4M-193.3M-115.3M-80.3M-48.0M-32.1M-23.1M-18.8M-18.1M
Capital spending-31.0K-2.60M-4.59M-686.0K-864.0K-1.36M-1.81M-1.43M-1.34M-215.0K
Free cash flow-129.8M-197.0M-197.9M-116.0M-81.2M-49.3M-33.9M-24.5M-20.1M-18.3M
Cash from investing-28.0K-2.60M-4.59M-686.0K-809.0K-1.36M-1.81M-1.43M-1.34M-215.0K
Cash from financing101.4M71.7M202.0M258.6M83.8M166.5M43.3M13.2M13.5M28.8M
Dividends paid-828.0K-1.38M
Share buybacks-340.0K
Change in cash-28.4M-125.3M4.06M142.6M2.64M117.1M9.44M-11.4M-6.55M10.4M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 17, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
S-3ASR · Registration statementNov 13, 2026Offer documentSEC
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
8-K · Current reportNov 13, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 28, 2026Big-stake noticeSEC
4 · Change in ownershipOct 14, 2026Insider tradeSEC
4 · Change in ownershipSep 28, 2026Insider tradeSEC
8-K · Current reportSep 28, 2026Current reportSEC
4 · Change in ownershipSep 23, 2026Insider tradeSEC
All 163 filings
FilingDateTypeFiled with
4/A · Change in ownership, amendedSep 18, 2026Insider tradeSEC
4/A · Change in ownership, amendedSep 18, 2026Insider tradeSEC
4/A · Change in ownership, amendedSep 18, 2026Insider tradeSEC
4/A · Change in ownership, amendedSep 18, 2026Insider tradeSEC
4 · Change in ownershipSep 17, 2026Insider tradeSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
144 · Notice of proposed saleSep 15, 2026Other filingsSEC
144 · Notice of proposed saleSep 14, 2026Other filingsSEC
144 · Notice of proposed saleSep 11, 2026Other filingsSEC
4 · Change in ownershipSep 10, 2026Insider tradeSEC
144 · Notice of proposed saleSep 9, 2026Other filingsSEC
144 · Notice of proposed saleSep 8, 2026Other filingsSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
8-K · Current reportSep 8, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
8-K · Current reportAug 13, 2026ResultsSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeAug 3, 2026Big-stake noticeSEC
8-K · Current reportJul 16, 2026Material contractSEC
8-K · Current reportJun 15, 2026Current reportSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
8-K · Current reportJun 3, 2026Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
8-K · Current reportMay 14, 2026ResultsSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 11, 2026Current reportSEC
4 · Change in ownershipApr 27, 2026Insider tradeSEC
ARS · Annual report to shareholdersApr 23, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 23, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2026Meeting noticeSEC
8-K · Current reportApr 21, 2026Current reportSEC
8-K · Current reportMar 19, 2026ResultsSEC
10-K · Annual reportMar 19, 2026Annual reportSEC
8-K · Current reportFeb 23, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 11, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 21, 2026Big-stake noticeSEC
8-K · Current reportDec 16, 2025Current reportSEC
8-K · Current reportNov 13, 2025ResultsSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportOct 23, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 17, 2025Big-stake noticeSEC
4 · Change in ownershipOct 9, 2025Insider tradeSEC
8-K · Current reportAug 13, 2025ResultsSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
EFFECT · Notice that a registration is effectiveJun 5, 2025Other filingsSEC
POS AM · Amendment to an effective registrationJun 2, 2025Offer documentSEC
4 · Change in ownershipMay 29, 2025Insider tradeSEC
4 · Change in ownershipMay 29, 2025Insider tradeSEC
4 · Change in ownershipMay 29, 2025Insider tradeSEC
4 · Change in ownershipMay 29, 2025Insider tradeSEC
424B3 · ProspectusMay 28, 2025Offer documentSEC
8-K · Current reportMay 28, 2025Meeting outcomeSEC
424B3 · ProspectusMay 14, 2025Offer documentSEC
8-K · Current reportMay 14, 2025ResultsSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
EFFECT · Notice that a registration is effectiveApr 21, 2025Other filingsSEC
POS AM · Amendment to an effective registrationApr 17, 2025Offer documentSEC
ARS · Annual report to shareholdersApr 16, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 16, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 16, 2025Meeting noticeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 2, 2025Insider tradeSEC
424B3 · ProspectusApr 1, 2025Offer documentSEC
8-K · Current reportApr 1, 2025Management or board changeSEC
4 · Change in ownershipMar 28, 2025Insider tradeSEC
POS EXMar 17, 2025Other filingsSEC
424B3 · ProspectusMar 17, 2025Offer documentSEC
8-K · Current reportMar 17, 2025ResultsSEC
10-K · Annual reportMar 17, 2025Annual reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 26, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 26, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 4, 2025Big-stake noticeSEC
424B3 · ProspectusJan 21, 2025Offer documentSEC
8-K · Current reportJan 21, 2025Current reportSEC
424B3 · ProspectusJan 13, 2025Offer documentSEC
8-K · Current reportJan 13, 2025Material contractSEC
4 · Change in ownershipDec 17, 2024Insider tradeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
4 · Change in ownershipNov 22, 2024Insider tradeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
424B3 · ProspectusNov 14, 2024Offer documentSEC
8-K · Current reportNov 14, 2024ResultsSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
424B3 · ProspectusNov 4, 2024Offer documentSEC
8-K · Current reportNov 4, 2024Current reportSEC
4 · Change in ownershipOct 7, 2024Insider tradeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
4 · Change in ownershipSep 12, 2024Insider tradeSEC
4 · Change in ownershipSep 10, 2024Insider tradeSEC
4 · Change in ownershipSep 3, 2024Insider tradeSEC
4 · Change in ownershipSep 3, 2024Insider tradeSEC
4 · Change in ownershipAug 30, 2024Insider tradeSEC
4 · Change in ownershipAug 26, 2024Insider tradeSEC
4 · Change in ownershipAug 22, 2024Insider tradeSEC
424B3 · ProspectusAug 14, 2024Offer documentSEC
424B3 · ProspectusAug 13, 2024Offer documentSEC
8-K · Current reportAug 13, 2024ResultsSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveJun 20, 2024Other filingsSEC
424B3 · ProspectusJun 18, 2024Offer documentSEC
8-K · Current reportJun 17, 2024Current reportSEC
CORRESP · Letter to the SECJun 14, 2024Other filingsSEC
UPLOAD · Letter from the SECJun 14, 2024Other filingsSEC
S-1 · Registration statementJun 11, 2024Offer documentSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
SC 13G · Big-stake noticeJun 7, 2024Big-stake noticeSEC
3 · Initial statement of ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 4, 2024Insider tradeSEC
SC 13D · Big-stake noticeJun 3, 2024Big-stake noticeSEC
SC 13D · Big-stake noticeJun 3, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeMay 31, 2024Big-stake noticeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 30, 2024Insider tradeSEC
4 · Change in ownershipMay 30, 2024Insider tradeSEC
4 · Change in ownershipMay 30, 2024Insider tradeSEC
4 · Change in ownershipMay 30, 2024Insider tradeSEC
4 · Change in ownershipMay 30, 2024Insider tradeSEC
4 · Change in ownershipMay 30, 2024Insider tradeSEC
4 · Change in ownershipMay 30, 2024Insider tradeSEC
S-8 · Registration statement for employee plansMay 30, 2024Offer documentSEC
8-K · Current reportMay 30, 2024Material contractSEC
3 · Initial statement of ownershipMay 24, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 24, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 24, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 24, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 24, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 24, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 24, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 24, 2024Insider tradeSEC
8-K · Current reportMay 24, 2024Current reportSEC
SEC STAFF ACTIONMay 24, 2024Other filingsSEC
CERT · Exchange's certificate of listingMay 24, 2024Other filingsSEC
CORRESP · Letter to the SECMay 22, 2024Other filingsSEC
10-12B/AMay 15, 2024Other filingsSEC
10-12B/AMay 8, 2024Other filingsSEC
CORRESP · Letter to the SECApr 25, 2024Other filingsSEC
10-12BApr 25, 2024Other filingsSEC
UPLOAD · Letter from the SECApr 4, 2024Other filingsSEC
DRSLTR · Letter to the SEC with a draftMar 4, 2024Other filingsSEC
DRS/A · Draft registration statement, amendedMar 4, 2024Offer documentSEC
UPLOAD · Letter from the SECFeb 29, 2024Other filingsSEC
DRS · Draft registration statementJan 26, 2024Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Inhibrx Biosciences, Inc.’s releases · as of Aug 7, 2026

Common shares
14,717,660
Fully diluted
14,717,660

Fully diluted

LineSharesAs of
Common shares14,717,660Aug 7, 2026

Warrants and options

Lot
Warrants · US$93.21 · expire about Jul 2036

Share count over time

CountShares
Aug 7, 202614,717,660

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Morgan Stanley1.32M9.0%US$132MSep 30, 2026
Perceptive Advisors LLC1.29M8.8%US$129MSep 30, 2026
Sanofi1.16M7.9%US$116MSep 30, 2026
Viking Global Investors LP1.11M7.5%US$111MSep 30, 2026
HighTower Advisors, LLC884K6.0%US$88.5MSep 30, 2026
Schonfeld Strategic Advisors LLC827K5.6%US$82.8MSep 30, 2026
BlackRock822K5.6%US$82.3MSep 30, 2026
Vanguard733K5.0%US$73.4MSep 30, 2026
TIG Advisors, LLC678K4.6%US$508KSep 30, 2026
State Street566K3.8%US$56.6MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Woodline Partners LP401K2.7%US$40.1MSep 30, 2026
Sofinnova Investments, Inc.392K2.7%US$39.2MSep 30, 2026
Capital Group362K2.5%US$36.3MSep 30, 2026
Parkman Healthcare Partners LLC360K2.4%US$36.1MSep 30, 2026
PFM Health Sciences, LP320K2.2%US$32.1MSep 30, 2026
Geode Capital255K1.7%US$25.6MSep 30, 2026
Goldman Sachs222K1.5%US$22.2MSep 30, 2026
Soleus Capital Management, L.P.210K1.4%US$21MSep 30, 2026
First Turn Management, LLC172K1.2%US$17.2MSep 30, 2026
Trails Edge Capital Partners, LP170K1.2%US$17MSep 30, 2026
Citigroup Inc164K1.1%US$16.4MSep 30, 2026
CDC Financial, Inc.132K0.90%US$13.2MSep 30, 2026
First Trust127K0.86%US$12.7MSep 30, 2026
Capitolis Liquid Global Markets LLC119K0.81%US$11.9MSep 30, 2026
Bank of America108K0.74%US$10.8MSep 30, 2026
Northern Trust105K0.72%US$10.5MSep 30, 2026
Healthcare Of Ontario Pension Plan Trust Fund97,0000.66%US$9.71MSep 30, 2026
Invesco92,5180.63%US$9.26MSep 30, 2026
Schwab87,4040.59%US$8.75MSep 30, 2026
BNP Paribas58,1850.40%US$5.82MSep 30, 2026
UBS52,8960.36%US$5.29MSep 30, 2026
Cormorant Asset Management, LP50,0000.34%US$5MSep 30, 2026
Ghisallo Capital Management LLC50,0000.34%US$5MSep 30, 2026
Voleon Capital Management LP47,6050.32%US$4.76MSep 30, 2026
Opaleye Management Inc.45,5000.31%US$4.55MSep 30, 2026
Nicholas Investment Partners, LP42,4830.29%US$4.25MSep 30, 2026
ArrowMark Colorado Holdings LLC35,1760.24%US$3.52MSep 30, 2026
Victory Capital33,0540.22%US$3.31MSep 30, 2026
Susquehanna32,0070.22%US$3.2MSep 30, 2026
Atom Investors LP30,7800.21%US$3.08MSep 30, 2026
Corient Private Wealth LP29,2760.20%US$2.93MSep 30, 2026
BNY26,1450.18%US$2.62MSep 30, 2026
Hudson Bay Capital Management LP25,0010.17%US$2.5MSep 30, 2026
Russell Investments Group, Ltd.24,8320.17%US$2.49MSep 30, 2026
Informed Momentum Co LLC23,3290.16%US$2.33MSep 30, 2026
Citadel22,8550.16%US$2.29MSep 30, 2026
Empirical Financial Services, LLC d.b.a. Empirical Wealth Management22,5840.15%US$2.26MSep 30, 2026
Nuveen21,2670.14%US$2.13MSep 30, 2026
D. E. Shaw & Co., Inc.18,8330.13%US$1.88MSep 30, 2026
Quantinno Capital Management LP17,3530.12%US$1.74MSep 30, 2026

This page holds 50 of 166 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF401K2.7%US$38MJun 30, 2026
Vanguard Total Stock Market Index Fund370K2.5%US$35MJun 30, 2026
SMALLCAP World Fund Inc353K2.4%US$33.5MJun 30, 2026
iShares Russell 2000 ETF244K1.7%US$23.1MJun 30, 2026
Vanguard Extended Market Index Fund110K0.75%US$10.4MJun 30, 2026
Fidelity Small Cap Index Fund104K0.71%US$8.53MJul 31, 2026
iShares Biotechnology ETF76,6250.52%US$7.26MJun 30, 2026
First Trust Small Cap Growth AlphaDEX Fund74,0910.50%US$6.08MJul 31, 2026
iShares Russell 2000 Growth ETF72,1260.49%US$6.83MJun 30, 2026
Eventide Healthcare & Life Sciences Fund61,5450.42%US$5.83MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund49,6230.34%US$5.16MMay 31, 2026
Vanguard Russell 2000 Index Fund46,5200.32%US$4.84MMay 31, 2026
First Trust Small Cap Core AlphaDEX Fund36,8270.25%US$3.02MJul 31, 2026
Hussman Strategic Market Cycle Fund30,0000.20%US$2.84MJun 30, 2026
Vanguard U.S. Momentum Factor ETF27,5540.19%US$2.87MMay 31, 2026
VictoryShares US Small Mid Cap Value Momentum ETF25,4180.17%US$2.41MJun 30, 2026
Schwab Small-Cap Index Fund23,1120.16%US$1.9MJul 31, 2026
State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF21,5990.15%US$2.05MJun 30, 2026
Fidelity Total Market Index Fund17,7810.12%US$1.85MMay 31, 2026
Master Small Cap Index Series17,7790.12%US$1.68MJun 30, 2026
Tax-Managed U.S. Mid & Small Cap Fund15,4390.10%US$1.27MJul 31, 2026
iShares Russell 2000 Value ETF15,1540.10%US$1.44MJun 30, 2026
Fidelity Series Total Market Index Fund14,5880.10%US$1.52MMay 31, 2026
iShares Core S&P Total U.S. Stock Market ETF13,8810.09%US$1.32MJun 30, 2026
Direxion Daily S&P Biotech Bull 3X Shares13,6270.09%US$1.12MJul 31, 2026
Goldman Sachs Small Cap Value Insights Fund13,0580.09%US$1.07MJul 31, 2026
Nuveen Small Cap Blend Index Fund12,5990.09%US$1.03MJul 31, 2026
Invesco RAFI US 1500 Small-Mid ETF10,8760.07%US$892KJul 31, 2026
EQ/2000 Managed Volatility Portfolio10,3750.07%US$983KJun 30, 2026
Tema Oncology ETF10,1700.07%US$1.06MMay 31, 2026
SMALLCAP World Fund9,7580.07%US$925KJun 30, 2026
Goldman Sachs Small Cap Equity Insights Fund9,6210.07%US$789KJul 31, 2026
Fidelity Nasdaq Composite Index Fund9,5720.07%US$996KMay 31, 2026
Victory Small Cap Stock Fund9,4140.06%US$772KJul 31, 2026
Vanguard Explorer Fund8,7000.06%US$714KJul 31, 2026
Fidelity Small Cap Growth Index Fund7,3540.05%US$697KJun 30, 2026
Vanguard Russell 2000 Value Index Fund7,1000.05%US$738KMay 31, 2026
LVIP State Street Small-Cap Index Fund6,8000.05%US$644KJun 30, 2026
First Trust Multi Cap Growth AlphaDEX Fund6,7140.05%US$551KJul 31, 2026
Small Cap Core Fund6,4390.04%US$610KJun 30, 2026
Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF6,3570.04%US$661KMay 31, 2026
Vanguard Balanced Index Fund6,3170.04%US$599KJun 30, 2026
Schwab Total Stock Market Index Fund6,0000.04%US$492KJul 31, 2026
Vanguard Institutional Total Stock Market Index Fund5,6140.04%US$532KJun 30, 2026
Nuveen Equity Index Fund5,1510.03%US$423KJul 31, 2026
Fidelity ZERO Total Market Index Fund5,1460.03%US$422KJul 31, 2026
EQ/Small Company Index Portfolio4,9400.03%US$468KJun 30, 2026
Fidelity Nasdaq Composite Index ETF4,9080.03%US$510KMay 31, 2026
Small Cap Index Fund4,7990.03%US$455KJun 30, 2026
Goldman Sachs Small Cap Growth Insights Fund4,7140.03%US$387KJul 31, 2026

This page holds 50 of 150 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Lappe Mark
Director, Officer: Chief Executive Officer
Buy2,470USD 84.07US$208KOct 14, 2026
Lappe Mark
Director, Officer: Chief Executive Officer
Buy2,470USD 85.00US$210KOct 14, 2026
Lappe Mark
Director, Officer: Chief Executive Officer
Buy100USD 85.76US$8,576Oct 14, 2026
Lappe Mark
Director, Officer: Chief Executive Officer
Buy2,449USD 84.07US$206KOct 14, 2026
Lappe Mark
Director, Officer: Chief Executive Officer
Buy2,451USD 85.00US$208KOct 14, 2026
Lappe Mark
Director, Officer: Chief Executive Officer
Buy100USD 85.76US$8,576Oct 14, 2026
Lappe Mark
Director, Officer: Chief Executive Officer
Buy1,500USD 98.88US$148KSep 28, 2026
Lappe Mark
Director, Officer: Chief Executive Officer
Buy3,000USD 101.70US$305KSep 28, 2026
Lappe Mark
Director, Officer: Chief Executive Officer
Buy3,324USD 98.87US$329KSep 25, 2026
Lappe Mark
Director, Officer: Chief Executive Officer
Buy2,176USD 99.60US$217KSep 25, 2026
All 25 trades
TradeTradeSharesPriceValueDate
Kayyem Jon Faiz
Director
Buy5,000USD 100.00US$500KSep 23, 2026
Kayyem Jon Faiz
Director
Buy5,000USD 100.00US$500KSep 16, 2026
Manhard Kimberly
Director
Sale500USD 105.05US$52,525Sep 15, 2026
Manhard Kimberly
Director
Sale500USD 110.26US$55,130Sep 14, 2026
Manhard Kimberly
Director
Sale500USD 111.78US$55,890Sep 11, 2026
Manhard Kimberly
Director
Sale500USD 115.80US$57,900Sep 9, 2026
Manhard Kimberly
Director
Sale500USD 115.14US$57,570Sep 8, 2026
Forsyth Douglas
Director
Buy2,500USD 114.65US$287KSep 8, 2026
Lappe Mark
Director, Officer: Chief Executive Officer
Buy5,895USD 99.29US$585KSep 8, 2026
Lappe Mark
Director, Officer: Chief Executive Officer
Buy6,605USD 100.64US$665KSep 8, 2026
Lappe Mark
Director, Officer: Chief Executive Officer
Buy1,100USD 107.12US$118KSep 8, 2026
Lappe Mark
Director, Officer: Chief Executive Officer
Buy500USD 108.24US$54,120Sep 8, 2026
Lappe Mark
Director, Officer: Chief Executive Officer
Buy1,219USD 111.88US$136KSep 8, 2026
Lappe Mark
Director, Officer: Chief Executive Officer
Buy9,681USD 112.28US$1.09MSep 8, 2026
Kayyem Jon Faiz
Director
Buy5,000USD 113.52US$568KSep 8, 2026

Big stakes

StakeStakeSharesDateFiling
Perceptive Advisors LLC9.99%1.49MJun 30, 2026Schedule 13G
Viking Global Investors LP9.30%1.38MJun 30, 2026Schedule 13G
Morgan Stanley7.90%1.16MDec 31, 2025Schedule 13G
Jon Faiz Kayyem7.90%1.15MJun 3, 2024Schedule 13D
Schonfeld Strategic Advisors LLC6.47%953KSep 30, 2026Schedule 13G
Mark Lappe6.40%925KSep 12, 2024Schedule 13D
BlackRock, Inc.5.30%768KDec 31, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Kimberly Manhard
Other companies: Connect Biopharma Holdings Limited (CHIEF DEVELOPMENT OFFICER · Since at least Nov 5, 2026); Inhibrx Inc (Director · Aug 18, 2020 – May 30, 2024 · Past); Heron Therapeutics, Inc. (EVP, Drug Development · Jan 10, 2014 – Apr 13, 2023 · Past); Ardea Biosciences Inc (SVP, Regulatory & Dev Ops · Oct 28, 2011 – Jun 19, 2012 · Past)
Director · Since at least May 24, 2024
Jon Faiz Kayyem
Other companies: Biodesix, Inc. (Director · Since at least Jan 1, 2024); Inhibrx Inc (Director · May 30, 2024 – May 30, 2024 · Past)
Director · Since at least May 24, 2024
Brendan P Eckelman
Other companies: Inhibrx Inc (Chief Scientific Officer · Aug 18, 2020 – May 28, 2024 · Past)
Chief Scientific Officer · May 24, 2024 – May 29, 2024 · Past
Ashraf AmanullahEVP, Chief Technical Operations Officer · Since at least Nov 5, 2026
Bonne AdamsVP, Operations · Since at least Nov 5, 2026
Brian LoboVP, Formulation Development and Drug Product Manufacturing · Since at least Nov 5, 2026
Carlos BaisEVP, Chief Scientific Officer · Since at least Apr 1, 2025
Dana Ebbets-ReedVP, Quality Assurance · Since at least Nov 5, 2026
Darren BrownVP, Analytical Development and Quality Control · Since at least Nov 5, 2026
David KaoVP, Regulatory Affairs · Since at least Nov 5, 2026
All 22 people
PersonSeat
David MatlyPresident · Since at least Apr 1, 2025
Douglas G. ForsythDirector · Since at least Sep 8, 2026
Jon Faiz KayyemDirector · Since at least Sep 23, 2026
Josep GarciaEVP, Chief Clinical Development Officer · Since at least Nov 4, 2025
Kate Burke C.P.A.VP, Accounting · Since at least Nov 4, 2026
Kelly DeckEVP, Chief Financial Officer · Since at least Apr 1, 2025
Kristiina VuoriDirector · Since at least Nov 5, 2026
Leah PollemaVP, General Counsel · Since at least Nov 5, 2026
Mark P. LappeFounder, Chief Executive Officer · Since at least Sep 8, 2026
Melissa MastersonVP, Access and Commercialization · Since at least Nov 5, 2026
Robert BoothroydVP, Medical Affairs and Business Development · Since at least Nov 5, 2026
Sean FlanaganVP, Sales · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Inhibrx Biosciences, Inc.